+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.

      Current Medicinal Chemistry
      Animals, Clinical Trials as Topic, Cyclic N-Oxides, chemistry, pharmacology, Dogs, Drug Design, Esters, Factor Xa Inhibitors, Haplorhini, Humans, Mice, Models, Biological, Models, Chemical, Molecular Conformation, Pyridines, Rabbits, Serine Endopeptidases, Signal Transduction, Treatment Outcome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Factor Xa (fXa) is a critical serine protease situated at the confluence of the intrinsic and extrinsic pathways of the blood coagulation cascade. FXa catalyses the conversion of prothrombin to thrombin via the prothrombinase complex. Its singular role in thrombin generation, coupled with its potentiating effects on clot formation render it an attractive target for therapeutic intervention. Otamixaban is a synthetically derived parenteral fXa inhibitor currently in late stage clinical development at Sanofi-Aventis for the management of acute coronary syndrome. Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

          Related collections

          Author and article information


          Comment on this article